US (or EU) ANDA: Fail f2 but pass BE? [Regulatives / Guidelines]

posted by jag009  – NJ, 2022-09-02 02:29 (624 d 06:46 ago) – Posting: # 23260
Views: 3,162

Thanks Osama.

That's my thinking as well since the BE studies were ~ 100% in ratios and reasonably sized.
But explaining to those non-pk/bioparm management f**ls who keep asking for risk assessment BS is a challenge.

❝ What about if you start with sampling time points @ 10 min ( EMA) and not @ 5min ( FDA)?

❝ have you tried with bootstrapping to overcome the high variability in the early sampling time points?


Unfortunately the guidance asked for 5 and 10 mins and on... evaluating the data now to see if there is need to evaluate..

john

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,641 registered users;
26 visitors (0 registered, 26 guests [including 4 identified bots]).
Forum time: 09:15 CEST (Europe/Vienna)

The most erroneous stories are those we think we know best–
and therefore never scrutinize or question.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5